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Summary
We examined the effect of simultaneously incorporat-
ing proline or proline-amino acid chimeras in posi-
tions 9, 10, and/or 11 of substance P, on the affinity for
the two NK-1 binding sites and on second-messenger
activation. Because these 3-substituted prolines con-
strain not only the (f,) values of the peptide back-
bone, but also the  space of the amino acid side
chain, we were able to gather data on the structural
requirements for high-affinity binding to the NK-1 re-
ceptor. We were able to confirm that this C-terminal
component is crucial and that it should adopt an ex-
tended conformation close to a polyproline II struc-
ture when bound to the receptor. The partial additivity
of these constraints, more specifically, for the NK-1M
site, suggests that the peptide backbone flexibility
around the hinge-point residue Gly9 is essential to
subtly position crucial side chains.
Introduction
NMR analyses of substance P (SP: H-Arg-Pro-Lys-Pro-
Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2) in micellar media
have demonstrated the presence of pure α helix or equi-
libria between α helix, 310-helix, or consecutive β-turns
[1–10]. Schwyzer et al. proposed that the highly posi-
tively charged N-terminal sequence of SP (address do-
main) led to an accumulation of SP on the anionic cell
surface, which induced an insertion of the hydrophobic
message domain in the membrane as an α helix aligned
with the lipid chains [11, 12]. From these studies, it has
been extrapolated that SP should adopt one of these
helical structures when bound to its receptor. However,
stabilization of helical structures in short, flexible pep-
tides is a well-known phenomenon readily observed in
both micellar media and organic cosolvents, such as
trifluoroethanol. A recurrent question remains, whether
these media stabilize a preexistent but poorly popu-
lated structure in aqueous solution, which represents
bioactive conformation, or if they induce helical struc-
tures unrelated to the conformation of the ligand bound
to its receptor.*Correspondence: lavielle@ccr.jussieu.frThe one-turn helical structure observed for residues
Pro4 to Phe8 of SP in methanol [13] has been validated
by the design of highly potent cyclic analogs of SP [14,
15]. In contrast, the U-turn structure proposed for the
C-terminal tripeptide, when in methanol, has been in-
validated because none of the substituted SP analogs
designed to probe this U-turn conformation turned out
to be active [16]. However, structure-activity relation-
ships performed with N-methylated aminoacids and/or
proline have suggested that the C-terminal residues of
SP adopt a more or less extended conformation, the
residue in position 9 (Gly9) being a hinge between these
two domains of SP [16]. More recently, we have shown
that the introduction of a 3-substituted proline (Figure
1) in position 10 or 11 of SP allowed us to define more
precisely the f angle (proline constraint) of residues 10
and 11 [17, 18]. This proline scaffold positions not only
the peptide backbone, but also the side chain of resi-
dues in a predefined orientation. According to the po-
tencies of these substituted SP analogs, the following
values for the torsion angles of Leu10 and Met11 resi-
dues, when bound to the NK-1 receptor, can be pro-
posed: f10 z −60°; ψ10 z 150°; χ1(10) z −60° ; χ2(10) z
180°; f11 z −60°; and χ1(11) z 180°. The χ1 torsion an-
gle of both Leu10 and Met11 could be determined by
comparison of the conformational spaces of corre-
sponding prolinoamino acids, and the χ2 torsion angle
was tentatively proposed, according to energy consid-
erations [17]. The introduction of a single 3-substituted
proline still allows fluctuations around the Ψ torsion an-
gles of residues 9, 10, and 11, preventing the determi-
nation of a unique conformation of the peptide back-
bone. Calculations performed on model dipeptides and
previous structure-activity relationships converge to a
destabilization of helical and poly γ-turn structures. Be-
cause the monosubstituted proline analogs, [Pro9]SP,
[Pt3Leu10]SP, [PC3Met11]SP, and [Pt3Met11]SP are all po-
tent agonists, there is an additional question as to the
additivity of these proline constraints in the C-terminal
tripeptide of SP: can all these constraints be simulta-
neously accepted within the binding site?
To get insight into the binding process, two to three con-
straints combining Pro, 3-substituted Pro, or N-methyl-
amino acid have been introduced in the C-terminal tri-
peptide of SP and SP(6-11), Gly-Leu-Met-NH2, and the
consequences of such modifications have been ana-
lyzed in terms of affinity and activity on the two specific
binding sites [19, 20] associated with the NK-1 recep-
tor. The structural effects of such constrained amino
acids in the SP sequence have also been evaluated on
model tripeptides by molecular modeling.
Results
Syntheses of SP and SP(6-11) Analogs Incorporating
Two or Three Constrained Residues
The C-terminal-constrained residues were coupled
manually to the MBHA resin to ensure complete cou-
pling with a minimum of equivalents used. Three to five
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equivalents with longer coupling times were needed for r
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Figure 1. Schematic Representation of 3-Substituted Prolines
3
d3 2 3 he binding affinities, and agonist or antagonist (partial
Table 1. Summary of Peptide Syntheses and Analytical Data
HPLC k (min)a Mass Spectral Analysis (M+H)+
Peptide Preparation Analytical Yield, % Purity, % Calculated Found
[Pt3Leu10,Pc3Met11]SP 11.55b 7.56f 13 >98 1399.77 1400.08l
[Pro9,Pt3Leu10,Pc3Met11]SP 9.81b 8.77g 15 >98 1439.80 1439.96l
[Pro9,Pc3Met11]SP 10.51c 6.27h 12 >98 1413.78 1413.91l
[Pro9,NMeLeu10,Pc3Met11]SP 13.33d 5.05h n.d.j,k >98 1427.79 1427.91l
[pGlu6,Pro9,Pc3Met11]SP(6-11) 17.96e 12.16i 13 >98 790.40 790.47m
[pGlu6,Pro9,NMeLeu10,Pc3Met11]SP(6-11) 22.16b 12.07i 4k 97 804.41 804.30m
a HPLC k = peptide retention time in solvent system: A (H2O/0.1% TFA) and B (CH3CN 60%/H2O 40%, TFA 0.1%).
b Semipreparative HPLC using a linear gradient over 30 min with 30%–70% B.
c Semipreparative HPLC using a linear gradient over 30 min with 35%–65% B.
d Semipreparative HPLC using a linear gradient over 30 min with 30%–65% B.
e Semipreparative HPLC using a linear gradient over 30 min with 40%–65% B.
f Analytical HPLC in isocratic mode with 56% B.
g Analytical HPLC in isocratic mode with 53% B at 45°C (at room temperature, peak dedoubling probably due to cis/trans isomerization of
amide bonds).
h Analytical HPLC in isocratic mode with 59% B.
i Analytical HPLC in isocratic mode with 55% B.
j Aggregates in 10% acetic acid. Dissolved in 50% acetic acid for purification.
k Another major product was isolated and identified as a Pro-deleted compound (ESI+ M+1 = 707.3 for the hexapeptide analog [pGlu6, Pro9,
NMeLeu10, Pc3Met11]SP(6-11)).
l Mass spectral analysis performed by MALDI-TOF.
m Mass spectral analysis performed by ESI+ analysis.c
3Met-NH2 (h) has been investigated using molecular
ynamics at 300 K. Values of χ1, χ2, and χ3 torsion an-
les correspond to a discrete number of conformations
2 or 3 per dihedral angle), and calculation of minimum-
nergy conformations enables us to describe the orien-
ation of the side chains. In contrast, f,ψ torsion angles
re more variable, and the comparison of the conforma-
ional space of the peptide backbone is best achieved
y calculating the size of the potential wells around
inimum-energy conformations [21]. Thus, conforma-
ional spaces of model peptides a–h were probed using
0 ns free dynamics at 300 K, and structures were saved
very 10 ps, yielding 1000 conformations for analysis.
tarting structures were built in extended conforma-
ions, but similar maps were obtained with longer dy-
amics (up to 24 ns) or from other starting conforma-
ions (helical, γ-turn). Ramachandran maps (Figure 2)
or residues Gly, Leu and Met in the reference tripeptide
a) are in agreement with those reported for these resi-
ues in proteins [22]. As previously reported, γ-turn con-
ormations [18] are excluded for residues preceding a
-ProAA (peptides c–h) and helical conformations are
estabilized for nonglycine residues preceding a 3-ProAA
peptides d–h) [23]. The same effects are observed for
esidue Pro preceding NMeLeu (peptide g).
harmacology of SP and SP(6-11) Analogs
he affinities of the SP analogs for the two specific
inding sites, NK-1M and NK-1m, associated with the
uman NK-1 receptor, have been measured on trans-
ected CHO cells. The more abundant binding site, NK-
M (85%), is labeled by [3H]SP and is coupled to cAMP
roduction, whereas the less abundant binding site,
K-1m (15%), is labeled by [3H]propionyl[Met(O2)11]
P(7-11) and is associated with IPs production [19].
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site) and NK-1m (minor site) and EC50 values (and pKB
values for partial agonists) for the cAMP and IPs path-
ways, are reported in Table 2. Deviations of the pharma-
cological behavior of these analogs compared either to
SP or [pGlu6, Pro9]SP(6-11) were evaluated with Stu-
dent’s t test. Although a factor of two to three was
sometimes found to be significant, we have classically
considered only a factor of ten or more to correspond
to a significant difference in the binding mechanism.
Undecapeptide Analogs Incorporating
One Constraint
We have previously shown that Gly9 can be replaced
by a proline [16, 19]. However, proline incorporation in
position 10 (Leu) or 11 (Met) was deleterious for both
affinities and activities on the two binding sites [16–18].
Reincorporation of one isopropyl side chain on position
3 of the proline scaffold led to [Pc3Leu10]SP and [Pt3Leu10]
SP analogs, only the trans analog being as potent as
SP on the two binding sites [18]. In the same manner,
reincorporation of the thioether side chain on the pro-
line scaffold led to the analogs [Pc3Met11]SP and
[Pt3Met11]SP being almost as potent as SP on the two
binding sites [17].
Undecapeptide Analogs Incorporating
Two Constraints
On the NK-1M-specific binding site, [Pt3Leu10, Pc3Met11]SP
was a slightly weaker competitor compared to SP (ra-tio, 3.8), being significantly less potent on the cAMP
pathway (EC50 = 53 nM) with a decreased efficacy
(53%) and being a partial agonist (KB = 3800 nM). On
the NK-1m binding site, [Pt3Leu10, Pc3Met11]SP is an
excellent competitor (Ki = 35 pM, 4-fold increase in af-
finity compared to SP); however its EC50 on IPs produc-
tion is only in the nanomolar range (EC50 = 5.4 nM),
being 7.7-times less potent than SP and [Pro9]SP. The
double-constrained SP analog [Pro9, Pc3Met11]SP is a
weaker competitor compared to SP on NK-1M-specific
binding (ratio, 53) and a partial agonist (EC50 = 30 nM,
31% efficacy, KB = 112 nM) on cAMP production. On
the NK-1m-specific binding sites [Pro9, Pc3Met11]SP is
only a slightly weaker competitor (Ki = 0.55 nM), but is
as potent as SP and [Pro9]SP on IPs production (EC50 =
1 nM; ratio, 1.4 compared to SP).
Undecapeptide Analogs Incorporating
Three Constraints
These two analogs are weak competitors for [3H]SP-
specific NK-1M binding (Ki = 180 and 62 nM, respec-
tively), compared to the nanomolar affinities of SP and
[Pro9]SP. Both analogs are also partial agonists on the
cAMP pathway (KB = 680 and 360 nM, respectively).
[Pro9, Pt3Leu10, Pc3Met11]SP induces, at the highest
concentration tested (10−5 M), only 16% of the maximal
response reached with SP, whereas [Pro9, NMeLeu10,
Pc3Met11]SP induces significant cAMP production
(EC = 35 nM, 50% efficacy). On the NK-1m-specific50
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558Table 2. Affinity and Activity of SP-Constrained Analogs
Ki, nM EC50, nM (% Efficacy) Ki, nM
Peptides NK-1M cAMP NK-1m EC50, nM (% Efficacy) IP
H-Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly9-Leu10- 1.6 ± 0.4 8 ± 2 0.13 ± 0.02 0.7 ± 0.3
Met11-NH2a
[Pro9]SPa 1.1 ± 0.1 10 ± 2 0.13 ± 0.02 0.7 ± 0.1
[Pro10]SP 24 ± 2*** 375 ± 50*** 3.7 ± 0.5** 3.0 ± 1.0
[Pro11]SPb 1150 ± 250*** >10,000*** 63 ± 6*** 56 ± 8**
[P3
CLeu10]SPc 465 ± 105*** >10,000 (12 ± 3%)*** 220 ± 30*** 260 ± 30 (49 ± 3%)**
pKB = 5.12 ± 0.06 (No antagonism)
[P3
t Leu10]SPc 0.86 ± 0.07 39 ± 9* 0.34 ± 0.09 2.1 ± 0.3*
[P3
CMet11]SPb 2.1 ± 0.1 35 ± 1** 0.08 ± 0.05 0.8 ± 0.1
[P3
t Met11]SPb 3.0 ± 0.5* 25 ± 2** 0.10 ± 0.007 1.4 ± 0.3
[P3
t Leu10,P3
CMet11]SP 6.0 ± 2.0** 53 ± 3 (53 ± 3%)*** 0.035 ± 0.015 5.4 ± 0.9**
pKB = 5.42 ± 0.09
[Pro9,P3
t Leu10,P3
CMet11]SP 180 ± 50*** 16 ± 3%*** 2.7 ± 0.2*** 4.7 ± 1.6
pKB = 6.17 ± 0.10
[Pro9,P3
CMet11]SP 85 ± 10*** 30 ± 2 (31 ± 4%)** 0.55 ± 0.1 1.0 ± 0.5
pKB = 6.95 ± 0.15
[Pro9, NMeLeu10,P3
CMet11]SP 62 ± 3*** 35 ± 5 (50 ± 2%)** 0.66 ± 0.15 4 ± 2 (85 ± 5%)
pKB = 6.44 ± 0.20
[pGlu6, Pro9]SP(6-11)a 490 ± 10 5200 ± 200 2.4 ± 0.5 2.7 ± 0.5
[pGlu6, Pro9,P3
CMet11]SP(6-11) >5000*** 10 ± 2% at 10−5*** 13 ± 4 17 ± 2 (75 ± 3%)**
[pGlu6, Pro9, NMeLeu10,P3
CMet11]SP (6-11) >5000*** 16 ± 3% at 10−5*** 3.5 ± 1 10 ± 2 (75 ± 2%)*
Statistical significance (Student’s t test) was evaluated against SP for SP analogs and [pGlu6, Pro9]SP(6-11) for SP(6-11) analogs as: ***p <
0.001; **0.001 < p < 0.01; *0.01 < p < 0.05.
a Data already published in [19].
b Data already published in [17].
c Data already published in [18].binding sites, [Pro9, Pt3Leu10, Pc3Met11]SP is a weak (
[competitor (ratio, 1:20 compared to SP, [2.70/0.13]),
Nwhereas [Pro9, NMeLeu10, Pc3Met11]SP is only a slightly
tweaker competitor (ratio, 1:5 compared to SP [4.0/0.7]).
SWhen IPs production is considered, both analogs are
ssix- to seven-times less potent than SP and [Pro9]SP
(EC50 = 4.7 and 4.0 nM, respectively). With [Pro9,
NMeLeu10, Pc3Met11]SP, the maximal response is not Cattained, IPs production plateau reaching 85% of the Sresponse induced by SP and [Pro9]SP. AHexapeptide Analog Incorporating Two Constraints
T
C-terminal hexapeptide analogs of SP are micromolar
i
agonists of SP on NK-1M-specific binding sites and on
a
cAMP production [19, 20]. But [pGlu6, Pro9]SP(6-11) is s
a nanomolar competitor on NK-1m binding sites (Ki = f
2.4 nM compared to 0.13 nM for SP and [Pro9]SP) and p
a potent analog on IPs production (EC50 = 2.7 nM), be- l
ing only four-times less potent than the undecapep- d
tides SP and [Pro9]SP [19, 20]. [pGlu6, Pro9, Pc3Met11] t
SP(6-11) behaves as [pGlu6, Pro9]SP(6-11) on NK-1M d
and is only a very weak competitor of [3H]propionyl G
[Met(O2)11]SP(7-11) (ratio, 1:100 compared to SP, but s
only 1:5 when compared to [pGlu6, Pro9]SP(6-11)) on r
the NK-1m binding sites. [pGlu6, Pro9, Pc3Met11]SP (
(6-11) is 24-times less potent than SP and [Pro9]SP, with
only 75% of their efficacies on IPs production, but only i
six-times less potent than [pGlu6, Pro9]SP(6-11). p
Hexapeptide Analog Incorporating Three Constraints a
Similar to [pGlu6, Pro9, Pc3Met11]SP(6-11) double-con- f
strained analog, [pGlu6, Pro9, NMeLeu10, Pc3Met11] c
SP(6-11) is inactive on NK-1M-specific binding sites. t
However, on NK-1m-specific binding sites, [pGlu6, Pro9, t
SNMeLeu10, Pc Met11]SP(6-11) was a weak competitor3ratio, 1:27 compared to SP and 1:1.5 compared to
pGlu6, Pro9]SP(6-11)). On IPs production, [pGlu6, Pro9,
MeLeu10, Pc3Met11]SP(6-11) was 15-times less potent
han SP and 3.7-times less potent than [pGlu6, Pro9]
P(6-11), reaching only 75% of the SP maximal re-
ponse.
omparative Analysis of the Backbone Conformational
paces of Model Tripeptides in Connection with High-
ffinity and Low-Affinity SP Analogs
he introduction of a proline or a prolinoamino acid lim-
ts the f angle to a (−90, −50) interval (peptides b, c,
nd d; Figure 2). This f angle restriction imposed by a
ingle substitution in the 9–11 segment is well tolerated
or both binding sites. The (f,ψ) space of nonglycine
receding residue is also mainly restricted to the upper
eft quadrant of the Ramachandran diagram (peptide
). Thus, the Gly-Leu-Pc3Met-NH2 analog shows that
he double restriction of ψ10 and f11 is well accommo-
ated in both binding sites. In the double constrained
ly-Pt3Leu-Pc3Met-NH2 agonist, three angles are re-
tricted: f10, ψ10, and f11, the conformational space of
esidue 10 being limited exclusively to the PPII region
peptide e).
Accessible conformations for Pc3Met and Pt3Leu are
dentical in peptides e–g (Figure 2). Concerning the
osition 9, the conformational spaces of peptide b
nd peptide f are identical. Therefore the lower affinity
or NK-1M observed with the [Pro9, Pc3Met11]SP analog
annot be explained by a restriction of the conforma-
ional space of the C-terminal tripeptide. Because the
riple-constrained analogs [Pro9, NMeLeu10, Pc3Met11]
P and [Pro9, Pt Leu10, Pc Met11]SP have low affinities3 3
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ψ9 angle. This is not the case for the NK-1m site, as
both [Pt3Leu10, Pc3Met11]SP and [Pro9, NMeLeu10,
Pc3Met11]SP analogs conserved high affinity. Indeed,
the conformational space of peptide g indicates that
residue 9 adopts a PPII conformation. As peptides
[Pt3Leu10, Pc3Met11]SP and [Pro9, NMeLeu10, Pc3Met11]
SP (model peptides e and g, respectively) have an affin-
ity similar to that of SP on the NK-1m binding site, the
lower affinity measured for [Pro9, Pt3Leu10, Pc3Met11]SP
(corresponding to model tripeptide h) cannot be ex-
plained by restriction of the conformational space of
the C-terminal tripeptide in this analog.
Discussion
Comparison between Single
and Multiple Constraints
The pharmacological properties of the monosubstituted
SP analogs containing either a prolinoleucine or a proli-
nomethionine, combined for the determination of the
minimum-energy conformations of Ac-Pc3Leu-NHMe
and Ac-Pt3Leu-NHMe, permitted us to identify the side
chain orientation of Leu10 (χ1 gauche+, χ2 trans) and
Met11 (χ1 trans) in the bioactive conformation of SP
[17, 18]. Further calculations indicated that helical con-
formations were destabilized for the residue preceding
a 3-substituted proline [18], thus showing that the
backbone of the C-terminal tripeptide of SP should
adopt a rather extended conformation when interacting
with the NK-1 receptor.
Several constraints were introduced simultaneously
in the C-terminal tripeptide of SP in order to further de-
fine the receptor-bound conformation of Gly-Leu-Met-
NH2. SP analogs [Pro9]SP, [Pt3Leu10]SP, [Pc3Met11]SP
(one constraint) and [Pt3Leu10, Pc3Met11]SP (two con-
straints in positions 10 and 11) have a similar affinity
when compared to SP for the NK-1M specific binding
site. In contrast, peptides [Pro9, Pc3Met11]SP (two con-
straints in positions 9 and 11), [Pro9, Pt3Leu10,
Pc3Met11]SP, and [Pro9, NMeLeu10, Pc3Met11]SP (three
constraints) have a lower affinity than SP for the NK-
1M binding site. For the NK-1m binding site, all these
peptides have a similar affinity compared to SP, except
[Pro9, Pt3Leu10, Pc3Met11]SP, the affinity of which was
significantly lower than that of SP. The lower affinities
of the most constrained SP analogs do not seem to
result from differences in the accessible conformations
of the C-terminal tripeptide in these SP analogs, as in-
ferred from comparative analysis of the low-energy
conformations of constrained Ac-Gly-Leu-Met-NH2 model
tripeptides. For both NK-1M- and NK-1m-specific bind-
ing sites, the common conformational space for high-
affinity analogs correspond to the upper left quadrant
of the Ramachandran diagram (extended region) and,
more specifically, to f,ψ values close to that of PPII
conformation (fw−78°, ψw149°) for the three residues
of the C-terminal tripeptide (although the ψ9 value re-
mains ambiguous for the NK-1M site). The lower affinity
of the most constrained SP analogs cannot be ascribed
to a noticeable change in accessible conformations of
the C-terminal part of these peptides, because all these
constrained analogs may adopt this extended PPIIstructure. One possible explanation is that the (f,ψ,χ)
angle restrictions are not optimal, and that, in a single
constrained analog, these nonoptimal values could be
compensated by small deviations around the other
nonrestrained torsion angles. Whatever the reason, the
bioactive conformation likely corresponds to an ex-
tended structure (β/PPII-like). In addition, it should be
noted that canonical PPII or β strand structures are
quite close to each other, as superimposition yields an
rmsd of only 0.13 nm when all heavy atoms are taken
in to account (in the Supplemental Data available with
this article online). The underlying assumption that
compounds of closely related chemical structure bind
to the receptor with a common binding process ending
in an identical, so-called, “bioactive conformation” is
an oversimplification. It is clear, now, that the backbone
conformations of different analogs do not have to be
strictly identical (“frozen”) for successful presentation
of the anchoring side chains in a correct three-dimen-
sional orientation for recognition. The receptor may ac-
cept slightly different conformations for different ligands
when bound to the receptor, and the binding process
must be viewed as a dynamic process (multistep and/
or sequential) in which mutual adaptation of the two
partners (ligand and receptor) cannot be possible if the
ligand is too constrained. Therefore, with this latter idea
in mind, Ki values indirectly reflect this dynamic process
and represent thermodynamic or steady-state values.
The affinity value, Ki, a thermodynamic parameter, gives
the affinity for the most stable state reached by the com-
petitor/receptor complex (the standard Gibb’s free en-
ergy G0 = −RT lnKi), assuming that equilibrium was
reached for both the radioligand used and the competi-
tor tested in the binding assay—differences in Ki values
for the two specific NK-1 binding sites could arise from
the experimental conditions per se. In the binding as-
say, equilibrium was reached for the radioligand (in
both cases), but the incubation time may have been
inadequate for the constrained competitors. Although
preincubation time prior to radioligand addition has not
been assayed for the analogs described herein, previ-
ous attempts with other families of constrained SP ana-
logs have always led to unaltered Ki values.
NK-1M Binding Site Determinants
For the NK-1M-specific binding site, it can be inferred
with all the SP analogs so far described that the unde-
capeptide sequence was required for nanomolar affin-
ity, and that phenylalanine-7, leucine-10, and methio-
nine-11 (or butyl, as in norleucine-11) side chains are
needed to retain high affinity. The binding subsites of
Phe7 [24] and Leu10 [18] side chains within the NK-1M-
specific binding site are rather restricted in volume and
flexibility, whereas the subsite for the methionine side
chain is larger and more adjustable. Position 9 consti-
tutes a hinge between the N-terminal residues, with the
helical core (residues 4–8), and the PPII conformation
of the C-terminal dipeptide Leu-Met-NH2. Depending
on the residue in position 9 (Gly, Ala [25], Pro [19], Sip
[26], Aib [25]), the three major anchoring points (Phe7,
Leu10, and Met11) of the undecapeptide SP analogs
may or may not be correctly positioned within the NK-
1M-specific binding site. Indeed, with an aminoisobu-
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560tyric acid (Aib) in position 9, this most stable confor-
mation cannot be reached within the ligand/receptor
complex [25].
The NK-1M-specific binding site accepts two con-
secutive constraints in positions 10 and 11 (Pt3Leu10
and Pc3Met11, respectively), but two constraints in posi-
tions 9 and 11 are not accepted (Pro9 and Pc3Met11,
respectively), although we did not assay a peptide con-
taining the trans-3-substituted proline residue. If one
assumes that equilibrium was reached for the 9/11-
disubstituted competitor, the results suggest that a
multistep or sequential binding should occur between
the competitor and the receptor. The binding of the iso-
butyl side chain may happen first to induce mutual
adaptation of both the ligand and the protein. When
positions 9 and 11 are simultaneously constrained, this
mutual adaptation cannot occur for the isobutyl side
chain, which has to worm its way into a small binding
subsite. Alternatively, if binding of the isobutyl side
chain is a “late event” in the binding process (occurring
after Phe7 and the constrained Met11 bindings), then
mutual adaptation of the Leu10 may not be possible
F
within its binding subsite with a constraint in position 1
9. A fortiori, three consecutive constrained amino acids
A
in the C-terminal tripeptide of SP cannot fit in the NK- [
1M-specific binding site. p
[
[NK-1m Binding Site Determinants
SWhen considering the NK-1m-specific binding site, the
P
relative orientation of the N-terminal residues with re- (
spect to the C-terminal dipeptide Leu-Met-NH2 is not P
Pthe central question, as the C-terminal hexapeptide ex-
hibits nanomolar affinity [19]. The N-terminal residues
of the undecapeptide SP analogs further stabilize the
ligand/NK-1 complex, but only by a factor of 10 to 20 a
([19]. These N-terminal residues may fit within binding
subsites, but only the presence and the relative orienta- h
[tion of phenylalanine-7 versus the C-terminal dipeptide
is critical. The binding subsite of Phe7 side chain within l
tthe receptor is rather restricted in volume and flexibility,
whereas the subsite for the methionine (or butyl, i.e., m
cnorleucine-11) side chain is larger and more adjust-
able. However, in contrast to the NK-1M-specific bind-
ing site, the stabilizing interaction of the isobutyl side D
Pchain of Leu10 is not as important, considering the high
affinity of [Gly(ΨCH2CH2)Gly10]SP [27]. Surprisingly, t
s[Pro10]SP was a poor competitor for the NK-1m-spe-
cific binding site, whereas reintroduction of an isobutyl N
Sside chain with a particular geometry, such as in
[Pt3Leu10]SP, completely restores the binding potential. t
sGlycine, Pro, and Ala are the best substituents in posi-
tion 9 to afford correct positioning of the two major an- s
bchoring points (Phe7 and Met11).
The isobutyl side chain is not a key element in the a
3stabilization of the competitor/receptor complex [27].
Indeed, the NK-1m-specific binding site not only ac- o
ocepts two constraints in positions 10 and 11 (Pt3Leu10
and Pc3Met11, respectively), but also in positions 9 k
tand 11 (Pro9 and Pc3Met11, respectively). The un-
decapeptide with three consecutive constraints (Pro9,
tNMeLeu10, and Pc3Met11) can also be accommodated
within the receptor (Ki[analog]/Ki[SP] close to 5). The most 1
Pconstrained SP analog, [Pro9, Pt Leu10, Pc Met11]SP, has3 3decreased affinity, but is still in the nanomolar range
Ki[analog]/Ki[SP] close to 20), similar to the affinity of
exapeptide analogs [pGlu6, Pro9]SP(6-11), septide and
Pro9, NMeLeu10, Pc3Met11]SP(6-11) (the ratio Ki[ana-
og]/Ki[septide] was close to 1). These data suggest
hat stabilization, by a factor of 10 to 20, of the N-ter-
inal residues is not readily accessible within the most
onstrained competitor/receptor complex.
iscrimination between the Two Binding Sites
osition 9 in SP constitutes a hinge point for recogni-
ion discrimination between NK-1M and NK-1m binding
ites. Indeed, as shown in the plot of NK-1m versus
K-1M affinities for C-terminal constrained analogs of
P previously or herein described (Figure 3), modifica-
ions in positions 10 or 11 led to parallel straight lines
hifting toward higher selectivity for the NK-1m binding
ite, the two or three constraint-containing peptides
eing the most selective. However with constrained an-
logs in position 9, the slope of the straight line (Figure
) is much lower, indicating a more pronounced effect
f such modifications on the NK-1M compared to those
n the NK-1m recognition process. This residue is also
nown to be a in a key position to switch from agonist
o antagonist behavior [25].
These constrained SP analogs gave the most selec-
ive undecapeptide ligands so far described for the NK-
m-specific binding site. [Pt3Leu10, Pc3Met11]SP, [Pro9,
c Met11]SP, [Pro9, NMeLeu10, Pc Met11]SP, and [Pro9,igure 3. Linear Regression Plot Obtained from NK-1M Versus NK-
m Binding Sites Affinity for Modified Peptide Analogs
nalogs were modified in position 9 ([Pro9]SP, [Sar9, Met(O2)11]SP,
Ala9]SP, [Aib9]SP, [β2-HAla9]SP, [β-Ala9]SP, [(pBz)Phe9]SP, [Sip9]SP),
osition 10 ([αMeLeu10]SP, [β2-Leu10]SP, [(pBz)Phe10]SP, [NMeLeu10]SP,
Pro10]SP, [Pc3Leu10]SP, [Pt3Leu10]SP), position 11 ([αMeMet11]SP,
Met(O2)11]SP, [Pro11]SP, [Pt3Met11]SP, [Pt3Met(O)11]SP, [Pt3Met(O2)11]
P, [Pc3Met11]SP, [Pc3Met(O)11]SP, [Pc3Met(O2)11]SP, [Nle11]SP, [(pBz)
he11]SP, or containing two ([Gly9(ψCH2CH2)Gly10]SP, [Gly9(ψCH2CH2)
S)Leu10]SP, [Gly9(ψCH2CH2)(R)Leu10]SP, [Apa(DLeu9-10)]SP, [Pt3Leu10,
c
3Met11]SP, [Pro9, Pc3Met11]SP), or three constraints ([Pro9, Pt3Leu10,
c
3Met11]SP, [Pro9, NMeLeu10, Pt3Met11]SP).3 3
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561P t3Leu10, Pc3Met11]SP are all about 100- to 200-times
more selective than any other analog for the NK-1m
binding site. [Pt3Leu10, Pc3Met11]SP was the best one
with a factor of selectivity comparable (around 200-
times) to the C-terminal hexapeptide analogs, but with
a subnanomolar affinity for the NK-1m-specific binding
site (Figure 3). This increase of selectivity came from an
increase in affinity for the NK-1m-specific binding site,
whereas the affinity for the NK-1M-specific binding site
remained unchanged.
Enthalpy and Entropy Effects
If the chemical modifications introduced in the C-ter-
minal region have restricted the C-terminal residues
into a conformation mimicking the receptor-bound con-
formation, then one would have expected to see a
significant increase in affinity due to a decrease in
the entropy penalty associated with constrained
analogs. This was not the case, as only a small (not
significant) increase was observed with two SP ana-
logs, [Pt3Leu10]SP for the NK-1M-specific binding site
(Ki[SP]/Ki[analog] = 2) and [Pt3Leu10, Pc3Met11]SP
(Ki[SP]/Ki[analog] = 4) on the NK-1m-specific binding
site. Thus, the decrease in entropy does not compen-
sate for a decrease in enthalpy, which may be tenta-
tively associated with a nonoptimal interaction of one
of the major anchoring points (methionine11 or isobutyl
side chain in position 10 and/or Phe7). Williams et al.
have proposed that residual mobility within a ligand/
receptor complex must decrease the enthalpy, and that
decreasing the flexibility of the anchoring points should
conversely increase the enthalpy [28, 29]. According to
Hunter and Thomas, an increase in enthalpy may also
correspond to a decrease in the number of partially
bound states, which are more flexible, and conse-
quently will be associated with a decrease in the en-
tropy of the system, thus tentatively explaining the en-
thalpy/entropy compensation [30]. Notable is the fact
that the solvation/desolvation question (entropy contri-
bution) has not been considered in these studies. This
contribution may be important within the NK-1 receptor,
as the three major anchoring points are hydrophobic
and their binding subsites are expected to be within a
hydrophobic environment with “specific” (frozen) water
molecules, which have to be displaced (entropy in-
crease) upon binding, as observed, for example, in the
growth hormone binding protein [31]. With the undeca-
peptide SP analogs, one can hypothesize that too
many constraints in the C-terminal tripeptide have de-
creased the number of less efficiently (partly) bound
states and thus decrease the entropy of the complex.
For the NK-1m-specific binding site, “only” Phe7 and
Met11 side chains are mandatory; thus, less partly (or
loosely) bound states may be involved in the binding
process compared to the NK-1M-specific binding, for
which the helical structure and Phe7, Leu10, and Met11
are necessary. One may hypothesize that the entropic
loss may be less than that in the NK-1M-specific bind-
ing site.
Implications for Current Models of GPCR Activation
A number of kinetic models have been developed to
describe the process of agonist activation [32]. In thepast few years, studies using fluorescence spectros-
copy (receptor-tagged or ligand- and receptor-tagged)
have provided insight into the structural changes that
occur upon agonist activation. Studies with purified, de-
tergent-solubilized β2-adrenergic receptor (β2AR) suggest
that the native receptor is a conformationally flexible
molecule that exists in at least two predominant confor-
mation substates in equilibrium [32, 33]. Agonists, par-
tial agonists, and neutral antagonists change both the
shape of the entire distribution and the population of
the conformational states [34–37]. Based on the lifetime
of the conformational states, the Kobilka group has
proposed a model with multiple agonist-specific recep-
tor states, wherein activation occurs through a se-
quence of conformational states, from the resting state
(R) to an intermediate state (R#) and, finally, the active
state (R*) [34–37]. Ki values may not reflect the agonist-
induced conformational state (R*) of the receptor if one
considers the relative populations of these R, R#, and
R* conformational states, unless the affinity of the ago-
nists dramatically increases for the R*. The agonist
binding precedes the conformational changes from R#
to R*; the active state is poorly populated even with a
saturated concentration of agonist. This R* state ap-
pears more flexible than the R and R# states, and tran-
sitions from R# to R* are relatively rare, high-energy
events. It has been shown that the rate of confor-
mational change is relatively slow for the β2AR (around
300 s), despite a rapid on-rate of agonist binding (t1/2
around 20 s). As such, these authors have proposed
a stepwise process for the agonist binding with some
interactions occurring rapidly (R to R#); subsequent in-
teractions “cannot form until stochastic conformational
fluctuations make the complete binding pocket acces-
sible,” leading to the R* state [34–37]. In the case of the
isoproterenol/β2AR complex the energy of binding has
been calculated to be 6–10 kcal/mol, in the absence of
G-protein. Precoupling of the receptor to the G-protein
in intact cells may accelerate the agonist-induced in-
terconversion.
By combining real-time measurements of agonist
binding by fluorescence resonance energy transfer and
second-messengers responses, the Galzi group has
shown that the NK-2 receptor may be sequentially acti-
vated, by NKA and analogs, from an R0 (inactive state)
to an R1 state (active conformation triggering calcium
response) and, with a slower kinetic, to an R2 state
(active conformation triggering cAMP response) [38–
40]. In the case of the NK-1 receptor, it would be tempt-
ing to speculate that the IPs and cAMP production cor-
responds to the same sequential events. However, this
does not seem to be the case, as we have previously
shown that the two binding sites do not interconvert,
at least within the span of hours that is the time scale
used in binding studies [41]. Moreover, the binding ki-
netics of the two analogs are reversed in intact CHO
cells (equilibrium reached in 100 min and 70 min for
[3H]SP and [3H]propionyl[Met(O2)11]SP(7-11), respec-
tively) and in membrane homogenates (equilibrium
reached in 10 min and 60 min for [3H]SP and [3H]propio-
nyl[Met(O2)11]SP(7-11), respectively) [19, 20].
Although the molecular basis of these two specific
binding sites is unknown, a few conclusions on their
respective activation patterns may be drawn from these
Chemistry & Biology
562proline-substituted SP analogs. All the nanomolar or s
ssubnanomolar competitors of the NK-1m-specific bind-
ing site display expected EC50 values for IPs prod- c
(uction within the 95% confidence interval, except
[Pt3Leu10, Pc3Met11]SP (Figure 4). The most selective f
ligand among the constrained analogs reported herein
is clearly seen out of the correlation of Ki (NK-1M) and t
cEC50 (cAMP) (Figure 4). If the Ki value reflects the (R)
and/or (R#) conformational states, the subsequent con- r
Nformational change to (R*) is less efficient, and the
binding energy is not transformed into an energy of ac- t
ativation for the conformational rearrangement within
the complex. When considering the NK-1M-specific c
ibinding site, all the analogs with two or three con-
straints are partial agonists (i.e., [Pt3Leu10, Pc3Met11]SP,
[Pro9, Pc3Met11]SP, [Pro9, Pt3Leu10, Pc3Met11]SP, and S
[Pro9, NMeLeu10, Pc3Met11]SP). Correlations are ob-
served between Ki (NK-1M) values and EC50 (cAMP) T
Pvalues for two of them, [Pt3Leu10, Pc3Met11]SP and
[Pro9, Pt3Leu10, Pc3Met11]SP; but [Pro9, Pc3Met11]SP f
tand [Pro9, NMeLeu10, Pc3Met11]SP are clearly outside
the 95% confidence interval of the correlation (Figure 7
w4). However when their pKB values were taken into ac-
count, these discrepancies were not so obvious (data C
onot shown in Figure 4). Neutral antagonists have been
obtained by restricting the flexibility around position 9 n
aof SP with a β-II# turn. Partial agonism has been ob-
served with some SP analogs bearing an aromatic sub- t
cstituent on the C-terminal residue [42, 43]. The
[Pt3Leu10, Pc3Met11]SP, [Pro9, Pc3Met11]SP, [Pro9, Pt3 s
uLeu10, Pc3Met11]SP, and [Pro9, NMeLeu10, Pc3Met11]SP
analogs show that there is no need for either an aro- n
omatic substituent or a β-II# turn structure [44, 45] to
confer partial antagonist properties on SP undecapep- o
ltide [46]. There is no clear relationship between the ag-
onist activity (either EC50 values or the plateau reached) t
cand the antagonist potency (pK ). Thus, additional con-Figure 4. Linear Regression Plot with 95% Confidence Interval of Ki (NK-1m) versus EC50 (PLC) and Ki (NK-1M) versus EC50 (AC)
Obtained from 103 analogs (data not shown) synthesized and pharmacologically tested in our laboratory.Btraints in the C-terminal SP tripeptide may eliminate
ome partially bound states within the ligand/receptor
omplex, which are normally involved in the productive
activation of second messenger pathways) transcon-
ormation of the receptor.
In conclusion, it has been clearly established with
hese proline-substituted SP analogs that the two spe-
ific binding sites associated with the NK-1 receptor
ecognize the C-terminal tripeptide of SP, Gly-Leu-Met-
H2, in an extended conformation (close to PPII). Addi-
ionally, as proposed for the NK-2 tachykinin receptor
nd the β2-AR, the binding of SP and the amino acids
onstituting its pharmacophore should be sequential,
nvolving mutual adaptation and partially bound states.
ignificance
he NK-1 receptor-bound conformation of SP (H-RPK
QQFFGLM-NH2) had been established as a highly
lexible N-terminal domain with a core helical struc-
ure (residues 4–8) and crucial residues in positions
, 10, and 11. However, there are divergent views on
hether there is a helical or a more or less extended
-terminal domain. To study the C-terminal structure
f SP, cis and trans prolinoleucine and prolinomethio-
ine (P3Leu, P3Met) were introduced at positions 10
nd 11 of SP. These amino acid chimeras, combining
he proline constraint (f angle value) with the side
hain of an amino acid, are useful for exploring the 
pace required for ligand/receptor interaction. The
se of such constrained analogs allowed the determi-
ation of the gauche+ (1) and trans (2) orientation
f the Leu10 side chain and the trans orientation (1)
f the Met11 side chain. In this study, two or three pro-
inoamino acid chimeras were thus incorporated in to
he SP sequence to observe the effects of additional
onstraints on the biological activity of the resulting
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563analogs. Results have shown that, although describ-
ing similar conformational spaces, no more than two
constraints were tolerated by the NK-1 receptor in po-
sitions 10 and 11. The nonadditivity of these con-
straints suggests that peptide backbone flexibility is
essential to precisely position the crucial recognition
side chains. These analogs were also useful for the
discrimination of recognition specificity between the
two binding sites associated with the NK-1 receptor.
Indeed, the NK-1m binding site can accommodate
more constraints than can that of NK-1M. In addition,
position 9 in SP was found to constitute a hinge point
for recognition discrimination between the two bind-
ing sites. Altogether, these multiconstrained analogs
favor the structurally similar PPII or  strands as the
conformational organization for the C-terminal part
of SP.
Experimental Procedures
Peptide Syntheses
Pt3Leu10 and Pc3Met11 have been synthesized as described pre-
viously [17, 18]. All Boc-amino acids were purchased from Senn
Chemicals Int. (Cachan, France). [Pt3Leu10, Pc3Met11]SP, [Pro9,
Pc3Met11]SP, [Pro9, Pt3Leu10, Pc3Met11]SP, [Pro9, NMeLeu10,
Pc3Met11]SP, [pGlu6, Pro9, Pc3Met11]SP(6-11), and [pGlu6, Pro9,
NMeLeu10, Pc3Met11]SP(6-11) were prepared by solid-phase pep-
tide synthesis on an a-p-methylbenzhydrylamine resin (MBHA
resin, substitution: 0.73 mmol/g of resin). In all cases, the three
C-terminal residues were coupled manually to the resin. Nonnatural
amino acids Fmoc-Pc3Met, Boc-Pt3Leu, Boc-Pc3Leu, Boc-pGlu,
and Boc-NMeLeu [47, 48] were assembled in a 3- or 5-fold excess
using HBTU as coupling reagent. Other Nα-Boc-amino acids were
assembled in a 10-fold excess using dicyclohexylcarbodiimide
and 1-hydroxybenzotriazole as coupling reagents. For peptides
[Pt3Leu10, Pc3Met11]SP and [Pro9, Pc3Met11]SP, synthesis was per-
formed on a 0.2 mmol scale and the resin was split in two after
coupling of Pt3Leu10. For peptides [Pro9, Pt3Leu10, Pc3Met11]SP,
[Pro9, NMeLeu10, Pc3Met11]SP, [pGlu6, Pro9, Pc3Met11]SP(6-11), and
[pGlu6, Pro9, NMeLeu10, Pc3Met11]SP(6-11), synthesis was per-
formed on a 0.3 mmol scale and the resin was split in half after
coupling of Pc3Met11. Then, after coupling of Pro9, the two sets
of resin were split in half again to synthesize undecapeptide and
hexapeptide analogs. In a typical manual procedure, the following
steps were performed in each cycle, with coupling efficiency moni-
tored with the Kaiser test: (1) activation of the Nα-Boc-amino acid
in NMP with the coupling reagents DCC/HOBt or HBTU (1 eq) and
DIEA (2 eq) for 5 min; (2) introduction to the reaction vessel, and
mixing for 4 to 16 hr; (3) washings with CH2Cl2, MeOH, and CH2Cl2;
(4) monitoring the completion of the reaction with the Kaiser test;
(5) Boc removal for 30 min with 50% TFA in CH2Cl2 and 1 mg in-
dole/100 ml of solution (or 20% piperidine for Fmoc-Pc3Met); (6)
washings with CH2Cl2; (7) neutralization with 10% DIEA in CH2Cl2;
and (8) washings with CH2Cl2, MeOH, and CH2Cl2. For the undeca-
peptides [Pt3Leu10, Pc3Met11]SP, [Pro9, Pc3Met11]SP, [Pro9,
Pt3Leu10, Pc3Met11]SP, and [Pro9, NMeLeu10, Pc3Met11]SP, the re-
maining couplings were carried out on an ABI Model 431A peptide
synthesizer. For the hexapeptides [pGlu6, Pro9, Pc3Met11]SP(6-11)
and [pGlu6, Pro9, NMeLeu10, Pc3Met11]SP(6-11), all residues were
coupled manually. After removal of the last Nα-Boc-protecting
group, the resin was dried in vacuo. The peptidyl resin was trans-
ferred into the Teflon vessel of an HF apparatus and the peptide
was cleaved from the resin by treatment with 1.5 ml of anisole, 0.25
ml of dimethyl sulfide, and 10 ml of anhydrous HF per gram of
peptide resin for 1 hr at 0°C. After evaporation in vacuo of HF and
the solvents over 2 hr, the resin was first washed three times with
Et2O and then subsequently extracted three times with 10% AcOH.
After lyophilization of the extract, the crude peptide was purified
by preparative reverse-phase HPLC with a Dionex apparatus, using
a 7.8–300 mm, C (7 m) SymmetryPrep column. The separation8was accomplished using various acetonitrile gradients in aqueous
0.1% TFA (see Table 1) at a flow rate of 6 ml/min, with UV detection
fixed at 220 nm. Before pooling, the purity of collected fractions
was analyzed by analytical HPLC (Waters Associates). The separa-
tion was performed on a 4 mm × 250 mm, C8 (10 m) Lichrosphere
100 RP column (Merck) in isocratic mode (see Table 1 for solvent
systems) at a flow rate of 1.5 ml/min with UV detection fixed at 220
nm. Further information on synthesized peptides are summarized
in Table 1.
Molecular Mechanics Calculation
Model tripeptides Ac-Gly-Leu-Met-NH2, Ac-Pro-Leu-Met-NH2,
Ac-Gly-Pt3Leu-Met-NH2, Ac-Gly-Leu-Pc3Met-NH2, Ac-Gly-Pt3Leu-
Pc3Met-NH2, Ac-Pro-Leu-Pc3Met-NH2, Ac-Pro-NMeLeu-Pc3Met-
NH2, and Ac-Pro-Pt3Leu-Pc3Met-NH2 were built with all the peptide
bonds in a trans conformation using the InsightII package (Accelrys
Inc.). Molecular mechanics calculations were performed with the
Discover program and CFF91 Forcefield. The electrostatic potential
was calculated in vacuo with a distance-dependent dielectric
screening of 4,r. Structures were minimized using steepest descent
and conjugate gradient algorithms until the gradient was less than
0.001 kcal , mol−1. Structures were gradually heated from 50 K to
300 K at 50 K intervals, in six steps of dynamics of 5 ps, with a
time-step of 1 fs. Then, the conformational space was generated
by 10 ns free dynamics at 300 K with a time-step of 1 fs. Structures
were saved every 10 ps, yielding 1000 conformations for analysis
[18, 21, 22].
Binding Assays/Second Messenger Pathways
CHO cells expressing 6 pmol of human NK-1 receptors per mg of
membrane proteins were used. For [3H]SP (120 Ci.mmol−1) binding
assays, 5 × 103 cells per well were seeded, and 5 × 104 cells per
well were needed for [3H]propionyl[Met(O2)11]SP(7-11) (100 Ci,
mmol−1) binding experiments [19]. Time incubations at 22°C were
100 min and 80 min, respectively, in Krebs-phosphate buffer [19,
20]. For second-messengers experiments, 105 CHO cells were la-
beled for 24 hr with [3H]inositol (0.5 Ci/well) or [3H]adenine (0.2
Ci/well) [19, 20]. Linear regressions between affinity and activity
were obtained with 103 analogs of SP (list not shown), with a 95%
confidence interval.
Supplemental Data
There is a supplemental figure (Figure S1) available at http://
www.chembiol.com/cgi/content/full/12/5/555/DC1/.
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